stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Current ratio
Rhythm Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 2.8×, down 1.6× from fiscal 2025 (4.4×). Over the past ten years it has ranged from 2.4× (fiscal 2016) to 22.4× (fiscal 2017); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.4× | 36.05% |
| FY2024 | 3.2× | (41.99%) |
| FY2023 | 5.6× | (37.24%) |
| FY2022 | 8.9× | 25.31% |
| FY2021 | 7.1× | (29.66%) |
| FY2020 | 10.1× | (18.48%) |
| FY2019 | 12.4× | (34.97%) |
| FY2018 | 19.0× | (15.05%) |
| FY2017 | 22.4× | 849.21% |
| FY2016 | 2.4× | (64.90%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.8× | (19.48%) |
| Jun 2026 | 3.5× | (17.18%) |
| Mar 2026 | 4.2× | (5.44%) |
| Dec 2025 | 4.4× | (7.13%) |
| 34 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ORKA Oruka Therapeutics, Inc. compare | 38.5× |
| PRAX Praxis Precision Medicines, Inc. compare | 15.7× |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.9× |
| ABVX Abivax SA Sponsored ADR compare | 6.0× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 5.9× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| CORT Corcept Therapeutics Incorporated compare | 3.0× |
| RYTM Rhythm Pharmaceuticals, Inc. | 2.8× |
| AXSM Axsome Therapeutics, Inc. compare | 1.4× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement